Top Markets
Coin of the day
Bio-Path Holdings, Inc. Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc.

BPTH
株式のランク #39843
Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on... Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation. The company's lead drug candidate, prexigebersen, is presently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, Bio-Path is advancing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia. Another promising asset, Liposomal STAT3, is in preclinical development, targeting pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development for various solid tumors. Bio-Path Holdings, Inc., founded in 2007, is headquartered in Bellaire, Texas.
株価
$0.035
最終同期: 2026-08-13
時価総額
$326.98K
変化(1日)
-12.50%
変化(1年)
-74.55%
US
取引 Bio-Path Holdings, Inc. (BPTH)

カテゴリー

Bio-Path Holdings, Inc.(BPTH)の配当利回りの履歴
Bio-Path Holdings, Inc.(銘柄コード: BPTH)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Bio-Path Holdings, Inc.(BPTH)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)